Merck KGaA Cancer Vaccine Studies On Clinical Hold Because Of Encephalitis, But AE Isn't In Lead Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
The single event occurred in an exploratory study with a very different patient population and regimen than Phase III trials of the vaccine against lung and breast cancers, leaving hope the setback will be short-lived.
You may also be interested in...
FDA lifts clinical hold on Merck KGaA's Stimuvax cancer vaccine study
Merck KGaA and U.S. affiliate EMD Serono will resume two studies of experimental cancer immunotherapy Stimuvax (BLP liposome vaccine) in patients with non-small cell lung cancer after FDA partially lifted the clinical hold it placed on the entire Stimuvax program in March (1"The Pink Sheet" DAILY, March 23, 2010). A third study, STRIDE, in advanced breast cancer, remains on hold while Merck and the agency decide on next steps, Merck said June 17. The hold followed a case of encephalitis observed in a patient enrolled in an exploratory Phase II trial of the vaccine in patients with multiple myeloma. Protocol in the two NSCLC trials, START and INSPIRE, are being amended to add specific safety measures in response to the serious adverse event
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.